President Donald Trump announced a comprehensive agreement Thursday with pharmaceutical manufacturers Eli Lilly and Novo Nordisk that will signficantly reduce prices for GLP-1 receptor agonist antiobesity medications and expand coverage through Medicare and Medicaid
How we reviewed this article: Helimeds has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical associations
But that hasnt happened, and the companys CEO said on its Q2 earnings call that the copycat GLP-1 market is of equal size to Novos business-likely due to the lower cost of compounded drugs
PERFORMANCE ELITE IV TREATMENT Members: $0 Add Ins ALA Athletic Cosmetic Wellness Detox Discover the antioxidant prowess of ALA (Alpha-Lipoic Acid), a vital compound that supports cellular energy production
Tom-Castro XM, Rodriguez-Arrastia M, Cardona D, Rueda-Ruzafa L, Molina-Torres G, Roman P